ABC | Volume 113, Nº2, August 2019

Original Article Maia et al Global Longitudinal Strain in Functional Capacity Arq Bras Cardiol. 2019; 113(2):188-194 Table 3 – Comparison between Group 1 - VO 2 max > 14 mL/kg/min and/or VE/VCO 2 slope < 35 and Group 2 - maxVO 2 < 14 mL/kg/ min and VE/VCO 2 slope > 35 Variables VO 2 > 14 mL/kg/min and/or VE/VCO 2 slope < 35 (n = 18) VO 2 < 14 mL/kg/min and VE/VCO 2 slope > 35 (n = 8) p value Age (years): Mean ± DP 45.7 ± 13.7 51.0 ± 10.0 0.334 (1) Gender: n (%) Men 11 (61.1) 4 (50.0) 0.683 (2) Women 7 (38.9) 4 (50.0) BMI (Kg/m²): Mean ± DP 29.4 ± 6.1 29.0 ± 3.7 0.849 (3) Comorbidities: n (%) SAH 13 (72.2) 7 (87.5) 0.628 (2) DM 10 (55.6) 6 (75.0) 0.420 (2) HF Etiology: n (%) Ischemic 5 (27.8) 1 (12.5) 0.628 (2) Hypertensive 7 (38.9) 3 (37.5) 1.000 (2) Myocarditis 3 (16.7) 1 (12.5) 1.000 (2) Chagas' disease 1 (5.6) 0 (0.0) 1.000 (2) Idiopatic 2 (11.1) 3 (37.5) 0.281 (2) Medication: n(%) ACEI/ARB 16 (88.9) 7 (87.5) 1.000 (2) Beta blocker 18 (100.0) 8 (100.0) 1.000 (2) Diuretics K-sparing 15 (83.3) 7 (87.5) 1.000 (2) LVEF (%) (mean ± DP) 30.6 ± 8.5 22.4 ± 6.0 0.021 (1) Strain (%) (mean ± DP) 8.6 ± 3.8 5.2 ± 3.3 0.037 (3) maxVO 2 (mean ± DP) 22.1 ± 10.0 12.4 ± 3.3 0.014 (3) VE/VCO 2 slope (mean ± DP) 35.8 ± 9.3 47.5 ± 5.8 0.003 (1) HRR (bpm) (mean ± DP) 20.2 ± 17.2 18.4 ± 19.0 0.004 (3) T 1/2 VO 2 (s) (mean ± DP) 147.5 ± 32.1 216.1 ± 25.7 < 0.001 (1) BMI: body mass index; SAH: hypertension; DM: diabetes mellitus; ACEI/ARB: converting the angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; LVEF: left ventricular ejection fraction; maxVO 2 : maximal oxygen consumption; VE/VCO 2 slope: slope of the VE/VCO 2 curve; HRR: heart rate recovery; T 1/2 VO 2 : time to VO 2 halving recovery. (1) – Student t test; (2) – Mann-Whitney test; (3) – chi-square test. 1. Arena R, Guazzi M, Cahalin LP, Myers J. Revisiting cardiopulmonary exercise testing applications in heart failure: aligning evidence with clinical practice. Exerc Sport Sci Rev. 2014;42(4):153-60. 2. Arena R, Myers J, Aslam SS, Varughese EB, Peberdy MA. Peak VO2 and VE/ VCO2 slope in patients with heart failure: a prognostic comparison. Am Heart J. 2004;147(2):354-60. 3. Guazzi M, Adams V, Conraads V, Halle M, Mezzani A, Vanhees L, et al. EACPR/AHA Scientific Statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Circulation. 2012;126(18):2261-74. 4. ParikhMN,LundLH,GodaA,ManciniD.Usefulnessofpeakexerciseoxygen consumptionandtheheart failuresurvivalscoretopredictsurvival inpatients >65 years of age with heart failure. Am J Cardiol. 2009;103(7):998-1002. 5. Arena R, Myers J, Abella J, Peberdy MA, Bensimhon D, Chase P, et al. The prognostic value of the heart rate response during exercise and recovery in patients with heart failure: Influence of beta-blockade. Int J Cardiol. 2010;138(2):166-73. 6. Freeman JV, Dewey FE, Hadlay DM, Myers J, Froelicher V. Autonomic nervous system interaction with the cardiovascular system during exercise. Prog Cardiovasc Dis. 2006;48(5):342-62. 7. Schwartz P, La Rovete MT, Vanoli E. Autonomic nervous system and sudden cardiacdeath.Experimentalbasisandclinicalobservationsforpost-myocardial infarction risk stratification. Circulation. 1992;85(1 Suppl):I77-91. 8. MaddoxT,RossC,HoP,MasoudiF,MAgidD,DaughertySL,etal.Theprognostic importanceofabnormalheartraterecoveryandchronotropicresponseamong exercise treadmill test patients. AmHear J. 2008;156(4):736-44. References 193